Donald E. Kohan

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

Donald E. Kohan, Paola Fioretto, Weihua Tang et al. · Kidney International · 2013 · 646 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption

You Fei Guan, Chuan‐Ming Hao, Dae Ryong et al. · Nature Medicine · 2005 · 602 citations

Medicine, Nephrology, Pharmacology +16

Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention

Hui Zhang, Aihua Zhang, Donald E. Kohan et al. · Proceedings of the National Academy of Sciences · 2005 · 318 citations

Life Sciences, Pharmacology, Physiology +15

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

Dick de Zeeuw, Blai Coll, Dennis L. Andress et al. · Journal of the American Society of Nephrology · 2014 · 299 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Collecting duct–specific knockout of endothelin-1 causes hypertension and sodium retention

Dowhan Ahn, Yuqiang Ge, Peter K. Stricklett et al. · Journal of Clinical Investigation · 2004 · 248 citations · Full text

Medicine, Nephrology, Physiology +17